PSA Velocity May be Irrelevant in Detection of Prostate Cancer

Measuring velocity of prostate cancer specific antigen rise over time may not be necessary before deciding whether a man needs a prostate biopsy, according to a large new study from urologists at US and European cancer centers.

 PSA velocity (PSAV) is a term used for change PSA levels in the blood over time. Instead of basing a decision to recommend biopsy (or not) on a single annual PSA reading, the urologist looks at a series of tests and calculates the rate of rise over time.

The new study suggests that calculating PSA velocity does not help to detect prostate cancer once PSA and age are taken into consideration.

This finding was reported by European Association of Urolog this August. “Some guidelines,” Scardino notes, “do incorporate PSAV cut points as an indication for biopsy.”

AUA New Guidelines on Prostate Cancer Screening

The American Urological Association (AUA) today issued new clinical guidance about prostate cancer screening. The guidelines were announced at the association’s annual meeting by Peter Carroll, chair of the panel that developed the Statement.  The AUA states that its guidelines directly contrast with recent recommendations issued by other major groups.

AUA advises that the prostate-specific antigen (PSA) test should be offered to well-informed men aged 40 years or older who have a life expectancy of at least 10 years.